Intravenous diltiazem for termination of reentrant supraventricular tachycardia: a placebo-controlled, randomized, double-blind, multicenter study

To assess the efficacy and safety of intravenous diltiazem, 54 patients with inducible sustained supraventricular tachycardia received diltiazem, 0.25 mg/kg or 0.25 mg/kg, followed by 0.35 mg/kg body weight, or placebo in a double-blind, randomized study. Twenty patients had atrioventricular (AV) no...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of the American College of Cardiology Vol. 13; no. 3; pp. 538 - 544
Main Authors:	Huycke, Edward C, Sung, Ruey J, Dias, Virgil C, Milstein, Simon, Hariman, Robert J, Platia, Edward V
Format:	Journal Article
Language:	English
Published:	New York, NY Elsevier Inc 01-03-1989 Elsevier Science
Subjects:	Adolescent Adult Aged Antiarythmic agents Biological and medical sciences Cardiovascular system Diltiazem - administration & dosage Diltiazem - adverse effects Double-Blind Method Electrocardiography Female Heart Conduction System - drug effects Hemodynamics - drug effects Humans Injections, Intravenous Male Medical sciences Middle Aged Pharmacology. Drug treatments Random Allocation Tachycardia, Supraventricular - drug therapy Wolff-Parkinson-White Syndrome - drug therapy Therapeutic efficiency Human Intravenous administration Reentry Arrhythmia Multicenter study Calcium antagonist Electrophysiology Cardiovascular disease Paroxysmal supraventricular tachycardia Chemotherapy Treatment Double blind study Antiarrhythmia agent
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!